Key result
Plasma angiopoietin 2 (ANGPT2) and a three-marker panel were significantly associated with the composite outcome of ESKD or a 40% decline in glomerular filtration rate across 3,519 participants.
Why the study?
Prognostic biomarkers reflective of underlying molecular mechanisms are critically needed for the effective management of diabetic kidney disease, the leading cause of end-stage kidney disease.
Does a three-marker panel including plasma ANGPT2 improve prediction of ESKD or a 40% decline in GFR in patients with diabetic kidney disease?
Population
Participants across discovery (N = 58), validation (N = 68), and replication cohorts (N = 3,183 and N = 210)
Comparison
A novel three-marker proteomics panel combined with standard clinical parameters vs standard clinical parameters alone
Design
Multicohort biomarker discovery and validation study with transcriptomic integration
Authors
Loading...
May refine DKD risk prediction beyond clinical parameters; hypothesis-generating pending prospective validation.
Cohort (n=3,519)
Yes
Does a three-marker panel including plasma ANGPT2 improve prediction of ESKD or a 40% decline in GFR in patients with diabetic kidney disease?
Plasma ANGPT2 is a promising prognostic endothelial biomarker for predicting the progression of diabetic kidney disease to ESKD or significant GFR decline.
Liu et al. (2022) conducted a cohort in Diabetic kidney disease (DKD) (n=3,519). Plasma angiopoietin 2 (ANGPT2) and three-marker panel was evaluated on Composite outcome of ESKD or a 40% decline in glomerular filtration rate. Plasma angiopoietin 2 (ANGPT2) and a three-marker panel were significantly associated with the composite outcome of ESKD or a 40% decline in glomerular filtration rate across 3,519 participants.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: